- Trials with a EudraCT protocol (318)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
318 result(s) found for: Shock.
Displaying page 9 of 16.
EudraCT Number: 2010-023495-11 | Sponsor Protocol Number: 2010-023495-11 | Start Date*: 2010-12-17 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: Esmolol to treat tachicardia in septic shock | |||||||||||||
Medical condition: septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002603-15 | Sponsor Protocol Number: GANCMV-2011 | Start Date*: 2011-11-21 | |||||||||||
Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA | |||||||||||||
Full Title: Early treatment with ganciclovir of active infection by cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock | |||||||||||||
Medical condition: Active infection with cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004247-37 | Sponsor Protocol Number: 38RC16.046 | Start Date*: 2017-05-04 |
Sponsor Name:University Hospital Grenoble | ||
Full Title: NA | ||
Medical condition: coagulopathy secondary to traumatic hemorrhagic shock | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005131-15 | Sponsor Protocol Number: 2008/0828 | Start Date*: 2008-12-19 | |||||||||||
Sponsor Name:CHRU de Lille | |||||||||||||
Full Title: ETUDE DE LA PHARMACOCINETIQUE DE L’ASSOCIATION PIPERACILLINE – TAZOBACTAM EN UTILISATION INTRA-VEINEUSE CONTINUE CHEZ L’ENFANT NEUTROPENIQUE FEBRILE . | |||||||||||||
Medical condition: febrile episodes in neutropenic patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000142-20 | Sponsor Protocol Number: 2003056 | Start Date*: 2004-10-01 | |||||||||||
Sponsor Name:Procter & Gamble Pharmaceuticals | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | |||||||||||||
Medical condition: Following as ST-wave elevation myocardial infarction, there is local ischemia. When reperfusion occurs, there is a complement mediated inflammatory reponse, known as reperfusion injury, and a syst... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001837-15 | Sponsor Protocol Number: NIMAO/2018-02/CR-01 | Start Date*: 2019-10-08 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001563-74 | Sponsor Protocol Number: PHRCN2018/LEVOHEARTSHOCK-LEVY/YB | Start Date*: 2020-07-24 | |||||||||||
Sponsor Name:CHRU de Nancy | |||||||||||||
Full Title: Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock St... | |||||||||||||
Medical condition: Cardiogenic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002636-31 | Sponsor Protocol Number: APHP211034 | Start Date*: 2022-09-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris/DRCI | ||
Full Title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the in... | ||
Medical condition: severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001650-26 | Sponsor Protocol Number: AnticholiumperSeIII | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D | |||||||||||||
Full Title: A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002028-19 | Sponsor Protocol Number: RH-CARD-Pharma001 | Start Date*: 2022-02-01 | |||||||||||
Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development – a 2x2 multifactorial, double-blinded, randomized, ... | |||||||||||||
Medical condition: Acute Myocardial Infarction with increased risk of Cardiogenic Shock. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006386-16 | Sponsor Protocol Number: P060226 | Start Date*: 2008-12-05 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: La reviviscence dans l'état de stress post-traumatique : une pathologie du rappel émotionnel ? Application thérapeutique | |||||||||||||
Medical condition: La reviviscence dans l'Etat de Stress Post-Traumatique | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003561-16 | Sponsor Protocol Number: TAK-242/01-04-TL-242-011 | Start Date*: 2005-12-21 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis | |||||||||||||
Medical condition: Severe sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002936-34 | Sponsor Protocol Number: iPROVE-O2-16 | Start Date*: 2017-01-30 |
Sponsor Name:Francisco Javier Belda Nacher | ||
Full Title: Effects on surgical site infection of an individualized perioperative openlung ventilatory strategy with high versus conventional inspiratory oxygen fraction (iPROVEO2). A comparative, prospective,... | ||
Medical condition: The study population will be patients who are scheduled for major abdominal (laparotomy and laparoscopic) surgery under general anaesthesia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005421-31 | Sponsor Protocol Number: | Start Date*: 2007-04-24 | |||||||||||
Sponsor Name:RER Saint Denis | |||||||||||||
Full Title: Effets hémodynamiques de l’administration de vasopressine au décours de l’Arrêt Cardio-Respiratoire chez des patients en état de choc réfractaire Hemodynamic effects of vasopressin administration i... | |||||||||||||
Medical condition: Patients admitted in ICU after sucessfully resuscitated cardiac arrest and developping a refractory shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002876-18 | Sponsor Protocol Number: 2011-002876-18 | Start Date*: 2011-12-19 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: CYCLosporinE A in reperfused acute myocardial infarction (CYCLE-Trial) | |||||||||||||
Medical condition: All (male and female) patients, aged over 18, presenting with a large STEMI not older than 4 hours (defined as angina pectoris or equivalent symptoms of more than 30 minutes duration within the las... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001930-26 | Sponsor Protocol Number: LEOC/FJD-14/01 | Start Date*: 2014-10-10 | |||||||||||
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ | |||||||||||||
Full Title: A randomized, evaluator blinded clinical trial to compare clinical efficacy of four different analgesic strategies in patients undergoing Extracorporeal Shock Wave Lithotripsy (ESWL). | |||||||||||||
Medical condition: Pain in Nephrolithiasis in whom Extracorporeal shock wave lithotripsy is indicated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004376-11 | Sponsor Protocol Number: AZM-MD-302 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||
Full Title: A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizat... | |||||||||||||
Medical condition: Ventricular arrhythmia in patients with implantable cardioverter-defibrillator (ICD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001754-21 | Sponsor Protocol Number: 2020-23 | Start Date*: 2020-05-19 |
Sponsor Name:Assistance Publique Hôpitaux de Marseille | ||
Full Title: An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease | ||
Medical condition: COVID-19-associated disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001408-41 | Sponsor Protocol Number: UKF-MIT-2020-01 | Start Date*: 2020-04-21 | |||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||
Full Title: A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia | |||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002241-12 | Sponsor Protocol Number: BI 1123.12 | Start Date*: 2004-12-23 |
Sponsor Name:Boehringer Ingelheim España S.A | ||
Full Title: Ensayo clínico de fase IIIb - IV, aleatorizado y abierto, para evaluar la eficacia y seguridad de tenecteplasa junto con heparina no fraccionada administrada previo a la realización de PCI primaria... | ||
Medical condition: Fibrinolisis previa a la PCI primaria en infarto agudo de miocardio | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
